Reposted by Stefan Schandelmaier
With over 96% of global trial data on this topic included, this #IPDMA, published in @lancetrespirmed.bsky.social and initiated by #EU-RESPONSE, provides the most comprehensive analysis for JAK inhibitors for adults hospitalized due to #COVID19.
Full article: www.thelancet.com/journals/lan...
thelancet.com
Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials
This IPDMA of RCTs in adults admitted to hospital due to COVID-19 found that JAK inhibitors
reduced mortality across all levels of respiratory support, independent of dexamethasone
or tocilizumab, and...